Jump to Main Content

FDA Alerts

FDA Approves Longer-Acting Calaspargase Pegol-mknl for ALL

The Food and Drug Administration approved calaspargase pegol-mknl (ASPARLAS, Servier Pharmaceuticals LLC), an asparagine specific enzyme, as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia (ALL) in pediatric and young adult patients age 1 month to 21 years.
Citations